AlgoraeOS Artificial Intelligence ('AI') Platform Successfully Launched

Key Highlights:

- Successful launch of AlgoraeOS platform, with Technology Readiness Level ("TRL") 3+
- AI models validated for fixed-dose combination ("FDC") drug target prediction
- High prediction correlation in major synergy metrics ranging from 0.91 – 0.98 "predicted" versus "actual"
- Next major milestone: combination drug candidate prediction, laboratory validation and implementation of intellectual property strategies.

Melbourne, Australia – 24 September 2024: Algorae Pharmaceuticals Limited (ASX: 1AI) is pleased to announce the successful launch of its proprietary artificial intelligence platform, AlgoraeOS.

The platform, launched on schedule, has achieved a Technology Readiness Level ("TRL") of 3+, an internationally recognized metric for evaluating technological progress. AlgoraeOS integrates four proprietary AI neural networks to analyse vast datasets, predicting fixed-dose combination ("FDC") drug targets. It operates on the 'Gadi' supercomputer, managed by National Computational Infrastructure ("NCI Australia"), which has previously been utilised for projects like climate modelling and natural disaster prediction.

To drive this platform to enterprise standards, Algorae is collaborating with leading experts from the UNSW AI Institute, with economic support from the data and digital specialist arm of Australia's national science agency, CSIRO Data61. AlgoraeOS is wholly owned by Algorae and will undergo iterative improvements over the next 2.5 years, with version 2.0 development already underway. Pleasingly, initial system training indicated high prediction correlation of major synergy metrics (Bliss, Loewe and HSA) ranging from 0.91 – 0.98 "predicted" versus "actual" data, facilitating high confidence in the model.

Chairman David Hainsworth added: *"The launch of AlgoraeOS marks a significant step in our strategy to leverage AI for developing fixed-dose combination drugs. By improving existing therapies rather than investing in new molecular entities, we can enhance drug efficacy while compressing the timelines and costs. This intersection of AI and drug development represents a major commercial opportunity for our shareholders and benefits the broader community through access to improved treatments."*

Initial in-silico FDC drug target predictions from AlgoraeOS are expected to be reported for company analysis in the coming weeks. Planning of pre-clinical assessments are under discussion with laboratory partners, focusing on development paths, intellectual property strategies, and potential commercial partnerships. Further updates on these collaborations will follow.

About AlgoraeOS

Algorae Operating System ('AlgoraeOS') is the Company's proprietary artificial intelligence ('AI') biopharmaceutical prediction platform under development at the University of New South Wales ('UNSW') and supported by co-funding from the CSIRO Next Generation AI Graduate Program.

Appendix 1: AlgoraeOS Presentation (below).

Algorae Pharmaceuticals Limited [ABN: 14 104 028 042]
Level 23, Rialto South Tower, 525 Collins St, Melbourne VIC 3000
P: +61 422 180 317

1

This announcement has been approved by the Board of Directors of Algorae Pharmaceuticals Limited.

End

For more information, please visit www.algoraepharma.com

Corporate and Media Enquiries
Mr Brad Dilkes - Director
P: +61 422 180 317
E: brad@algoraepharma.com

About Algorae Pharmaceuticals

Algorae is a pharmaceutical development company focussed on addressing unmet medical needs through the discovery and development of novel treatments. The Company has assembled a proficient R&D team and established collaborations with reputable academic institutions to advance its promising drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, AI-168 for cardiovascular disease and NTCELL for Parkinson's disease.

Algorae intends to expand its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform. Known as Algorae Operating System (AlgoraeOS), the AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the aim of AlgoraeOS is to uncover synergistic drug combinations that lead to the development of novel and effective treatments for any medical condition, aligning with Algorae's commitment to address unmet medical needs. Algorae is listed and publicly traded on the Australian Stock Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Algorae Pharmaceuticals Limited [ABN: 14 104 028 042]
Level 23, Rialto South Tower, 525 Collins St, Melbourne VIC 3000
P: +61 422 180 317

2

Disclaimer: Important Information

Not an offer of Securities. This document has been independently prepared by Algorae Pharmaceuticals Ltd (Algorae) and is provided for informational purposes only. This document does not constitute or contain an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Algorae. This document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction (in particular, the United States), or a securities recommendation. This document is not a prospectus, product disclosure statement or other offering document under Australian law or any other law and will not be lodged with the ASIC. Summary Information This document contains a summary of information about Algorae and its activities that is current as at the date of this document. The information in this document is general in nature and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in Algorae or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) (Corporations Act). No Liability The information contained in this document has been prepared in good faith by Algorae, however no guarantee representation or warranty expressed or implied is or will be made by any person (including Algorae and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document. To the maximum extent permitted by law, Algorae and its affiliates and their directors, officers employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice. No responsibility or liability is assumed by Algorae or any of its affiliates for updating Not Financial Product Advice This document does not it constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in Algorae is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document. Information in this Document is Confidential This document and the information contained within it are strictly confidential and are intended for the exclusive benefit of the persons to whom it is given. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of Algorae. By receiving this document, you agree to keep the information confidential, not to disclose any of the information contained in this document to any other person and not to copy, use, publish, record or reproduce the information in this document without the prior written consent of Algorae, which may be withheld in its absolute discretion. Acceptance By attending an investor presentation or briefing, or accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as set any information in this document or to inform any recipient of any new or more accurate information or any errors or mis-descriptions of which Algorae and any of its affiliates or advisers may become aware. Forward Looking Statements Certain information in this document refers to the intentions of Algorae, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause Algorae actual results, performance or achievements to differ from those referred to in this document. Accordingly Algorae and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated. Statements contained in this document, including but not limited to those regarding the possible or assumed future costs, performance, dividends, returns, revenue, exchange rates, potential growth of Algorae, industry growth or other projections and any estimated company earnings are or may be forward looking statements. Forward-looking statements can generally be identified by the use of words such as 'project', 'foresee', 'plan', 'expect', 'aim', 'intend', 'anticipate', 'believe', 'estimate', 'may', 'should', 'will' or similar expressions. These statements relate to future events and expectations and as such involve known and unknown risks and significant uncertainties, many of which are outside the control of Algorae. Actual results, performance, actions and developments of Algorae may differ materially from those expressed or implied by the forward-looking statements in this document. Such forward-looking statements speak only as of the date of this document. There can be no assurance that actual outcomes will not differ materially from these statements. To the maximum extent permitted by law, Algorae and any of its affiliates and their directors, officers, employees, agents, associates and advisers: disclaim any obligations or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions; do not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this document, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement; and disclaim all responsibility and liability for these forward- looking statements (including, without limitation, liability for negligence).

AlgoraeOS Highlights

❖ Version 1.0 successfully launched

❖ AI models successfully validated

❖ Technology readiness level (TRL): 3+

❖ Consistent performance in all models

❖ Version 2.0 development commenced

❖ Creation of drug candidate IP leveraged to pharmaceutical "patent cliff"

❖ Next catalyst: combination drug prediction

AI x Combination Drugs in Pharmaceuticals

❖ AI promises to become the starting point of all biopharmaceutical research and development

❖ AlgoraeOS employs vast multi-omic databases and AI to increase the pace and reduce the cost of discovering new drug candidates for any disease condition

❖ Intellectual property generated by predicting unexpected outcomes (including synergistic mechanism of action) between two known drugs or molecules

❖ Combination drug candidates leverage accelerated FDA pathways, utilising existing medical and scientific data available on each individual drug

❖ Combination drug candidates developed by AlgoraeOS will be developed internally or designated for commercial partnership by the Company

*** Reference: Clinical Development Success Rates and Contributing Factors 2011-2020, Bio Stats*

AlgoraeOS
AI-enabled Drug Combination Prediction

AlgoraeOS Development	SEP - JUN	JUL	AUG	SEP	FUTURE
	Platform Development	Models Optimised	Validation Testing	Ver 1.0	Platform Enhancement

AlgoraeOS Version 1.0 launched on schedule with a 3+ TRL, now actively predicting fixed-dose combination (FDC) drug targets capable of developing patent protected market monopolies. Discussions with laboratory facilities are underway for pre-clinical assessments, with a focus on defining development pathways, commercialisation strategies, including partnerships with big pharmaceutical companies seeking to protect future revenue streams.

AlgoraeOS is academically constructed and distinct from international peers, producing commercial-grade drug candidate predictions. The Platform will continue evolving with additional data sets, metrics and capabilities planned in Version 2.0 and beyond.

AlgoraeOS
AI-enabled Drug Synergy Predictor

Training Data + **AI Models** = **Drug Targets**

Training Data	AI Models	Drug Targets
>300K Drug Combinations	Customised ANN Architecture	In Silico Screening
>2K Drugs	Synergy Scores Prediction	Prioritisation
>180 Cell Lines	Validation	Laboratory Testing
>20 Tissues	TRL: 3+	

In **pharmaceuticals**, "synergy" refers to the phenomenon where two or more drugs or compounds work together to produce a therapeutic effect that is greater than the sum of their individual effects. This indicates that the drugs enhance each other's therapeutic efficacy. This interaction can lead to enhanced efficacy, reduced doses of each drug, and potentially fewer side effects compared to using a single drug.

Combination Drugs: New and Improved Pharmaceuticals

Fixed-dose combination drugs (FDCs) are medicines that comprises two or more active pharmaceutical ingredients combined in a single dosage form. Developers may leverage existing data generated for each individual drug by other R&D companies and organisations over decades to develop improved pharmaceutical treatments.

Advantages of fixed dose combination drugs include:

❖ Enhanced efficacy: combining drugs with different mechanisms of action can lead to a more potent and synergistic therapeutic effect.

❖ Reduced side effects: combining drugs may allow for lower individual doses of each drug, minimising side effects.

❖ Broad spectrum of activity: combination drugs can be effective against a wider range of targets, pathogens, or disease processes.

❖ Optimised drug delivery: formulating multiple drugs in a single dosage form allows for more precise control over drug release and delivery. This can improve the pharmacokinetics and pharmacodynamics of the drugs, leading to better therapeutic outcomes.

Patent Cliff

AlgoraeOS: Generating Novel Drug Candidates

US$200 Billion per annum of revenue at risk to Big Pharma through to 2030

190 drugs, including 69 blockbusters exit patent protection before 2030

Top 10 big pharma have an average of **44% of revenues at risk**. Total sales in 2023 was $521 Billion

$152 Billion of M&A activity in 2023, the highest since 2019

Big pharma hold approx. **$171 Billion of cash** reserves

Revenue growth has a 7 times greater impact on total shareholder returns (TSR) than margin growth

AlgoraeOS
Business Model

Multiple routes for generating shareholder value, including high value partnering and licensing opportunities.

AlgoraeOS is designed to predict synergistic drug combinations that lead to new and improved treatments and intellectual property profiles. Our strategy leverages a significant economic opportunity created by big pharma's investment into combatting the "patent cliff", the expected lost revenues from patent expirations over major drugs.

AlgoraeOS

Pipeline

Develop an internal pipeline of fixed dose combination drugs with an accelerated pathway to approval

Partners

Partner in therapeutic areas where the commercial impetus is the pharmaceutical "patent cliff", leveraging partner knowledge and development capabilities

Data

License subsets of data to augment AlgoraeOS to maximise pipeline and partnership value drivers

BioPharma with AI-enabled Business Models

Algorae is the only AI-enabled biopharma company focused on fixed-dose combination drugs (FDCs) and cannabinoid combination drugs

		USD	AUD
1AI	Algorae Pharmaceuticals Ltd	$7.9M	$11.8M*
RXRX	Recursion Pharmaceuticals Inc	$1.90B	$2.83B
RLAY	Relay Therapeutics Inc	$1.22B	$1.82B
EXAI	Excientia Plc	$635M	$947M
SDGR	Schrodinger Inc	$1.45B	$2.16B
ABCL	AbCellera Biologics	$763M	$1.14B
LTRN	Lantern Pharma Inc	$42.9M	$64M

*prices as at 23 September 2024

Major value drivers within AI-enabled biopharmaceutical companies include generation of drug targets, advancement of AI-discovered drug candidates and commercial collaborations with other, often larger, pharmaceutical companies.

AI Development Team

Dr. James McKenna (Algorae)
Chief Scientific Officer

A/Prof. Fatemeh Vafaee (UNSW)
Artificial Intelligence | PI

Dr. Muhammad Heydari (UNSW)
Artificial Intelligence

Mr. Thomas Marsland (UNSW)
Artificial Intelligence

Ms. Parvin Mansouri (UNSW)
Artificial Intelligence

Mr. Bryan Lye (UNSW)
Artificial Intelligence

AlgoraeOS Project Partners

AI Model

Features, Architecture & Validation

AI Model
Features, Architecture & Validation
Four Customised Artificial Neural Network (ANN) Architectures

Features
❖ Cell Line: Gene Expression; Drug: Chemistry

Models for Predicting Drug Synergy Scores
❖ **ZIP (Zero Interaction Potency):** a mathematical model used in pharmacology to quantify & evaluate drug interactions.
❖ **BLISS:** an important independence model in drug discovery, allowing researchers to systematically evaluate the effects of drug combinations. Assumes that drugs work independently, and their effects can be combined to assess synergy.
❖ **LOEWE:** a particularly valuable tool in pharmacology for determining optimal drug dosages in combination therapies. Synergy occurs if the combined effect is more than expected from their additive effect.
❖ **HSA (Highest Single Agent):** a valuable synergy model in early-stage drug development for quickly determining whether a combination of drugs performs better than the most effective drug used alone.

Better than or comparable to SOA
❖ Standard metrics (MSE or MAE)

Validation
❖ K-fold cross-validation
❖ Leave-drug-out CV (*de novo*)

AI Model: Features

Cell Lines: Gene Expression

Gene expression profiles
- ❖ DepMap repository
- ❖ Normalised, batch-corrected

Selected genes/features
- ❖ Entire transcriptome: **~20K**
- ❖ LINCS Landmark genes: **978**
- ❖ Targets of drugs: **1,162**

Drugs: Chemical Structure

- ❖ Molecular graph
- ❖ Mogan fingerprint (256)

AlgoraeOS Ver. 1 Statistics

Version 1 Dataset

~1.5M Records

Drugs	Cell Lines	Tissues
8370	2041	32

Dual-Therapy

~750K Records

~75K
Unique Pairs

~660K
Unique Trios

Drugs	Cell Lines	Tissues
4328	295	17

Gene Expression Data

~470K Records

~22K
Unique Pairs

~400K
Unique Trios

Drugs	Cell Lines	Tissues
3168	150 - 170	15

16

AI Model: ANN Architecture
## Loewe Metric, 300K Training Data

Feature Fusion

❖ Early fusion

❖ Late fusion

6-Layer Feedforward Neural Network

❖ Architecture:
- Input layer: 6274 <256,256,1162>
- 4 x Hidden layers:
  - 1st hidden layer: 2048
  - 2nd hidden layer: 1042
  - 3rd hidden layer: 128
  - 4th hidden layer: 16
- Output layer: 1

>15M Parameters

AI Model: Performance

Correlation Results (Actual Values vs Predicted Values)

5-fold Cross-Validation
(Bliss, HSA and ZIP Metrics)30K Training Data

|	
Corr (Actual Values, Predicted Values) = 0.98	**BLISS**
Corr (Actual Values, Predicted Values) = 0.91	**HSA**
Corr (Actual Values, Predicted Values) = 0.91	**ZIP**

Correlation results measure how well the predicted values correlate with the actual synergy scores. Values close to 1.0 indicate a strong predictive model.

Drug Combination Prediction
In Silico Screening

Prioritised Predictions

In Silico Screening
❖ Fixed dose combination (FDC) drugs
❖ Initial focus on cannabidiol combinations
❖ Subsequent versions to compare all registered drugs

Prioritisation Based On
❖ Prediction score
❖ Metric agnostic
❖ Cell line
❖ No reported drug-to-drug interaction (DDI)
❖ No reported toxicity (TOXRIC)

NEXT STEPS

Laboratory Testing

❖ Pre-clinical assessment of predicted FDC drugs

❖ Discussions commenced with laboratories

Intellectual Property

❖ IP assessment for commercial potential

Pipeline, Partnerships & Platform

❖ Develop internal pipeline of FDC drugs

❖ Partner in complex therapeutic areas, leveraging partner knowledge and development capabilities

❖ License subsets of platform to maximise value drivers

Website: https://algoraepharma.com

Media Inquiries: brad@algoraepharma.com

Level 23, Rialto South Tower

525 Collins Street, Melbourne VIC 3000